Selected article for: "human virus and SARS cov"
Author: Devi Dayal; Saniya Gupta
Title: Connecting BCG Vaccination and COVID-19: Additional Data
  • Document date: 2020_4_8
    • ID: by4aefjc_12
    Snippet: is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.07.20053272 doi: medRxiv preprint simplex virus and human papilloma virus, a favourable in vitro or in vivo effect has indeed been observed in various studies (11). Based on the hypothesis that BCG vaccination may induce (partial) protection against susceptibility to and/or severity of SARS-CoV-2 infection even during the epidemic, some c.....
    Document: is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.07.20053272 doi: medRxiv preprint simplex virus and human papilloma virus, a favourable in vitro or in vivo effect has indeed been observed in various studies (11). Based on the hypothesis that BCG vaccination may induce (partial) protection against susceptibility to and/or severity of SARS-CoV-2 infection even during the epidemic, some countries like Australia and the Netherlands which do not practice routine BCG vaccination have been really quick to launch phase 3 clinical trials (12, 13).

    Search related documents:
    Co phrase search for related documents
    • BCG vaccination and routine BCG vaccination: 1, 2, 3, 4, 5
    • BCG vaccination and SARS infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • BCG vaccination and SARS infection severity: 1, 2
    • BCG vaccination and susceptibility protection: 1
    • BCG vaccination and vivo effect: 1
    • clinical trial and human papilloma: 1
    • clinical trial and human papilloma virus: 1
    • clinical trial and phase launch: 1, 2
    • clinical trial and SARS infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical trial and SARS infection severity: 1, 2, 3, 4, 5, 6, 7
    • clinical trial and vivo effect: 1
    • epidemic SARS infection severity and SARS infection: 1
    • epidemic SARS infection severity and SARS infection severity: 1
    • partial susceptibility protection and susceptibility protection: 1
    • routine BCG vaccination and SARS infection: 1
    • SARS infection and susceptibility protection: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • SARS infection and vivo effect: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • SARS infection severity and susceptibility protection: 1
    • SARS infection severity and vivo effect: 1